Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era

20051,262 citationsJournal Articlebronze Open Access

Authors

Bengt Nilsson · University of Gothenburg

Per Bümming · University of Gothenburg

Jeanne M. Meis‐Kindblom · University of Gothenburg

Anders Odén · University of Gothenburg

Aydin Dortok · Novartis (United States)

Bengt Gustavsson · Novartis (Sweden)

Katarzyna Sablinska ·

Abstract

GIST has been under recognized: Its incidence, prevalence, and clinical aggressiveness also have been underestimated. Currently existing risk-group stratification systems based on tumor size and mitotic rate delineate GIST patients who have a poor prognosis. Prognostication in patients with GIST can be refined using a proposed risk score based solely on tumor size and proliferative index.

Topics & Keywords

Gastrointestinal Tumor Research and Treatment Gastric Cancer Management and Outcomes Gastrointestinal disorders and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 103, Issue 4, pp. 821-829

DOI: 10.1002/cncr.20862

Field-Weighted Citation Impact: 33.92